Xitoglip-M 50mg/500mg Tablet is a combination oral antihyperglycemic agent containing Sitagliptin 50mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone. Xitoglip-M is typically prescribed as an adjunct to lifestyle modifications including diet and exercise to improve glycemic parameters such as fasting blood glucose and HbA1c. It is important to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, which often subside with continued use. Dose adjustments may be necessary based on clinical response and tolerability. Xitoglip-M should be used under medical supervision with regular monitoring of blood glucose and renal function.